Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 80 clinical trials
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

gonadotropin-releasing hormone analog (GnRH agonist) may fight prostate cancer by lowering the levels of androgen the body makes. Prednisone may either kill the tumor cells or stop them from dividing. Giving

  • 5 views
  • 06 Jun, 2022
  • 1 location
Insulin Resistance Following ADT for Prostate CA

Prostate cancer is the most common cancer in men in the United States. Suppression of male hormone levels by using GnRH agonist ("hormone blocking therapy") for a few years is routinely used to

  • 0 views
  • 24 Jul, 2022
  • 1 location
Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders (MONACO)

under stimulation for IVF/ICSI: up to three MNC cycles (group 1) versus a single GnRH antagonist CFA (group 2).

  • 0 views
  • 10 Apr, 2022
  • 1 location
Neuropeptides in Human Reproduction

opioid hormone that is blocked by naloxone. We hypothesize that naloxone, by blocking dynorphin, will stimulate production of GnRH and kisspeptin, 2 other naturally occurring reproductive hormones

klinefelter syndrome
kisspeptin
reproductive hormones
hypogonadism
Accepts healthy volunteers
  • 98 views
  • 07 Jul, 2022
  • 1 location
CLBR Per Initial Cycle With Different Starting Dose in Aged Patients With Poor Ovarian Reservation: 300IU Versus 150IU

time to live birth(TTLB) of the first stimulation cycle were compared between a starting dose of 300IU or 150IU rFSH in controlled ovarian stimulation with gonadotropin-releasing hormone(GnRH

antral follicle count
ovarian hyperstimulation
gonal-f
mullerian inhibiting substance
ovarian hyperstimulation syndrome
  • 8 views
  • 25 Mar, 2022
  • 1 location
The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer (ADTPSMA2)

Thirty-five men with newly diagnosed, metastatic prostate cancer are scanned with 18F-PSMA 1007 PET/CT at baseline, 3 weeks after the initiation of GnRH-antagonist, at one year and at the time

adenocarcinoma
prostate cancer metastatic
gonadorelin
metastatic prostate cancer
castration-resistant prostate cancer
  • 0 views
  • 21 Feb, 2022
  • 1 location
Skeletal Health and Bone Marrow Composition Among Youth

-releasing hormone (GnRH) agonist medications. This has the possibility of impacting bone development as sex steroids are important to bone mass development. In this multi-site study, the investigators will

  • 0 views
  • 04 Sep, 2021
  • 1 location
Administration of Kisspeptin to Subjects With Reproductive Disorders

The investigators are seeking participants for a study of the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occuring hormone in humans that stimulates the production of reproductive hormones. The investigators hypothesize that kisspeptin administration will be a useful tool for characterizing certain reproductive disorders.

klinefelter syndrome
hirsutism
replacement therapy
kisspeptin
reproductive hormones
  • 808 views
  • 22 Jul, 2022
  • 1 location
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD)

(mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically) who have been treated with gonadotropin-releasing hormone (GnRH)-analogue (LHRH agonists/antagonists) continuously

Accepts healthy volunteers
  • 0 views
  • 11 May, 2022
  • 1 location
Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

protective against cardiac steatosis-induced dysfunction, by suppressing ovarian sex hormones with a GnRH antagonist and repeating the fasting studies with and without estrogen add-back. 30 female subjects

  • 0 views
  • 03 Feb, 2021
  • 1 location